15 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
a Worse Outcome Across Multiple Tumor Types N 100 500 1000 3000 Hazard Ratio WORSE OUTCOME CCNE1 Alteration Type Amplification Amplification … (2018) [OS] Stronach (2018) [PFS] Hazard Ratio N 100 500 1000 Cyclin E1 Alteration Amplification Amplification+ Overexpression PF 1 O 1 O 2 PF 3 O 3 O 4 O
8-K
EX-99.2
ZNTL
Zentalis Pharmaceuticals Inc
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
1000 3000 Hazard Ratio WORSE OUTCOME CCNE1 Alteration Type Amplification Amplification + Overexpression Overexpression RFS1 CSS1 OS2 RFS3 CSS3 PFS4 … OS6 Hazard Ratio WORSE OUTCOME CCNE1 Alteration Type Amplification Amplification + Overexpression N 100 500 1000 Cyclin E1
40 *H-scores calculated
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
13 Sep 23
Regulation FD Disclosure
7:00am
Chemotherapy Treatment Independent of Platinum-Sensitivity Status Hazard Ratio Cyclin E1 Alteration Worse outcome 6 Studies; n=5404 4 Studies where timing … Independent of Chemotherapy Backbone H-Score ≤ 50 (N=12) H-Score 50 (N=78) Median PFS (months) 3.25 9.86 Hazard Ratio (95% CI) 0.37 (0.18 – 0.79) Log-rank p
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Aug 23
Regulation FD Disclosure
4:15pm
Outcome Following Platinum-Based Chemotherapy Treatment Independent of Platinum-Sensitivity Status Hazard Ratio Cyclin E1 Alteration Worse outcome 6 … (2023) [OS] han [ ] Ka [ ] Nakay [ ] etersen [ ] t r en (20 ) ] Pils [ ] Strona [ ] Stronach (201 ) ] 1 2 3 4 5 Hazard Ratio N 100 500 1000 Cyclin E1
8-K
EX-99.2
ZNTL
Zentalis Pharmaceuticals Inc
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
Platinum-Based Chemotherapy Treatment Independent of Platinum-Sensitivity Status Hazard Ratio Cyclin E1 Alteration Worse outcome 6 Studies; n=5404 4 … E1+ Tumors Independent of Chemotherapy Backbone H-Score ≤ 50 (N=12) H-Score 50 (N=78) Median PFS (months) 3.25 9.86 Hazard Ratio (95% CI) 0.37
8-K
EX-99.3
jhuv19m4r191l7y mm
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
mj52 hk9auu9c2ns
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-10.1
ndsn58 bjctixkl3vrcv
2 Oct 20
Entry into a Material Definitive Agreement
4:51pm
DRS
EX-10.8
f8l9x2 xnzp6n34
10 Jul 20
Draft registration statement
12:00am
DRS
EX-10.11
fe3ja5 xu
10 Jul 20
Draft registration statement
12:00am
DRS
EX-10.9
0koeznia
10 Jul 20
Draft registration statement
12:00am
S-1
EX-10.8
kdophkxrav gq13
6 Mar 20
IPO registration
5:05pm
S-1
EX-10.9
atdeh0m3xxy
6 Mar 20
IPO registration
5:05pm
S-1
EX-10.11
4ugtftn3b k75oim9h3a
6 Mar 20
IPO registration
5:05pm
- Prev
- 1
- Next